All-oral longer regimens are effective for the management of multidrug resistant tuberculosis in high burden settings.
Palwasha Y KhanMolly F FrankeCatherine HewisonKwonjune J SeungHelena HuergaSidney AtwoodSaman AhmedMunira KhanTanha SultanaMohammad Manzur-Ul-AlamLuan Nguyen Quang VoLeonid LeccaKalkidan YaeSerik KozhabekovMeseret TamiratAlain GelinStalz C VilbrunMarina KikvidzeJamil FaqirzaiAbdullaat KadyrovAlena SkrahinaAnita MesicNana AvagyanMathieu BastardMichael L RichUzma KhanCarole D MitnickPublished in: The European respiratory journal (2021)
Among individuals receiving bedaquiline and/or delamanid as part of a multidrug regimen for drug-resistant tuberculosis, there was no significant difference between those who received an injectable and those who did not regarding culture conversion within 6 months. The potential contribution of injectable agents in the treatment of drug-resistant tuberculosis among those who were HIV positive requires further study.
Keyphrases
- drug resistant
- multidrug resistant
- hiv positive
- acinetobacter baumannii
- mycobacterium tuberculosis
- gram negative
- hiv aids
- pulmonary tuberculosis
- men who have sex with men
- antiretroviral therapy
- klebsiella pneumoniae
- south africa
- hyaluronic acid
- adverse drug
- human immunodeficiency virus
- emergency department
- combination therapy
- risk factors
- hiv infected
- escherichia coli
- smoking cessation